Adjudication rates in oncology trials average roughly 40 percent, and can climb as high as 65 percent in some indications. In other words, two qualified, independent readers can disagree on nearly two out of every three participants in certain trials....
As an organization, MERIT has a diverse staff that work together collectively as a team and have a high amount of autonomy for their work. In my role I get to learn about many people’s jobs and expertise, which I enjoy and can apply to...
One of the things I enjoy most about working at MERIT is the culture. There’s a strong sense of collaboration, and it feels like everyone is working toward improving and growing together. I also really appreciate how the company invests in its people by encouraging...
For any ophthalmic drug program, one practical question ends up shaping the entire nonclinical plan: for this program, with this route of delivery, which species actually belongs in the study protocol? The answer varies more than newcomers often expect, and it hinges less on convention...
Reader variability is the natural disagreement that appears when two qualified radiologists review the same scans, apply the same criteria, and still reach different conclusions about a participant’s disease. It is a well-documented and persistent source of difficulty in oncology imaging, and in a clinical...
Before an ophthalmic drug candidate reaches its first nonclinical study, someone has to answer a deceptively simple question: which animal do we test it in? The answer depends on where the drug will be delivered, how it will be dosed, and how closely the model's...
I love working at MERIT because as an entry-level clinical research professional, this has been an incredible environment to learn how oncology research and clinical trials operate. Working across different oncology studies has given me the opportunity to see how trial and project needs vary...
I am passionate about innovation, healthcare, and science. Clinical research gives me the opportunity to contribute to the field in a creative and meaningful way – whether that means exploring new endpoints, improving methodologies, or ensuring the highest level of accuracy and quality in our...
For sponsors and CROs designing a trial in idiopathic pulmonary fibrosis (IPF), the underlying biology isn't background reading. It directly shapes which endpoints are likely to detect a treatment effect, how patient populations should be stratified, and how well the resulting data package will hold...
Ocular findings have a way of showing up uninvited, and when they do, the quality of the eye exam behind that finding can determine whether a program moves forward or stalls....
As a Business Development Associate supporting MERIT’s oncology team, I often get to be the first point of contact with clients. My day-to-day focuses on building relationships with sponsors, understanding their imaging endpoint needs, and developing tailored proposals....
As Therapeutic Area Lead for Ophthalmology, I serve as a technical and strategic resource across the business development and sales teams. I join capabilities calls to answer sponsor questions, assist with budget and proposal reviews to make sure we're presenting our services accurately and compellingly,...